![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » PAR RECEIVES FDA APPROVAL OF MEGACE ES FOR ANOREXIA
PAR RECEIVES FDA APPROVAL OF MEGACE ES FOR ANOREXIA
July 11, 2005
Par has received FDA approval for Megace ES, a concentrated oral suspension for the treatment of anorexia, cachexia or an unexplained, significant weight loss in patients with a diagnosis of AIDS.
Megace ES (megestrol acetate) is Par's first branded pharmaceutical product approved by the FDA. Megace ES is an advanced formulation of megestrol acetate oral suspension, the appetite stimulant most commonly prescribed by physicians. Megace ES can be taken without regard to meals and is dosed at one-fourth the volume of the original product.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct